A previous study carried out by a researcher showed the efficacy of oral administration of LMWGAL-TF in an animal model of metabolic syndrome (Kandhare et al., 2015[9]) and diabetes mellitus (Kamble et al., 2013[8]) at 60 mg/kg/day (90-days) and 50 mg/kg/day (for 21 days) respectively. The gene discussed is TF; the disease is metabolic syndrome.